Literature DB >> 19782051

Oleanane triterpenoid CDDO-Me inhibits growth and induces apoptosis in prostate cancer cells through a ROS-dependent mechanism.

Dorrah Deeb1, Xiaohua Gao, Hao Jiang, Branislava Janic, Ali S Arbab, Yon Rojanasakul, Scott A Dulchavsky, Subhash C Gautam.   

Abstract

CDDO-Me, a synthetic triterpenoid derived from oleanolic acid, is a promising anticancer agent that has shown strong activity against a wide variety of cancer types in vitro and in vivo. We have previously shown that CDDO-Me induces apoptosis in prostate cancer cells irrespective of their hormonal status. To further understand the proapoptotic mechanism of CDDO-Me, we investigated the role of reactive oxygen species (ROS) in mediating the apoptosis inducing activity of CDDO-Me in LNCaP and PC-3 prostate cancer cell lines. Here, we show that CDDO-Me induces ROS generation from both nonmitochondrial and mitochondrial sources, which is associated with the induction of apoptosis as characterized by increased annexin V-binding, cleavage of PARP-1 and procaspases-3, -8, -9, loss of mitochondrial membrane potential and release of cytochrome c. In addition, CDDO-Me inhibited cell survival Akt, NF-kappaB and mTOR signaling proteins. The inhibition of ROS generation by N-acetylcysteine (NAC) or by overexpression of antioxidant enzymes glutathione peroxidase (GPx) and superoxide dismutase-1 (SOD-1) prevented CDDO-Me-induced apoptosis. Pretreatment with NAC blocked annexin V-binding, cleavage of PARP-1 and procaspases-3, -8, -9, loss of mitochondrial membrane potential and release of cytochrome c by CDDO-Me. NAC also prevented the inhibition of constitutively active Akt, NF-kappaB and mTOR by CDDO-Me. Together, these data indicate that ROS plays an essential role in the induction of apoptosis by CDDO-Me in prostate cancer cells.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19782051      PMCID: PMC2822351          DOI: 10.1016/j.bcp.2009.09.006

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  44 in total

1.  Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor.

Authors:  A Brunet; A Bonni; M J Zigmond; M Z Lin; P Juo; L S Hu; M J Anderson; K C Arden; J Blenis; M E Greenberg
Journal:  Cell       Date:  1999-03-19       Impact factor: 41.582

Review 2.  The phosphatidylinositol 3-Kinase AKT pathway in human cancer.

Authors:  Igor Vivanco; Charles L Sawyers
Journal:  Nat Rev Cancer       Date:  2002-07       Impact factor: 60.716

3.  Novel triterpenoid CDDO-Me is a potent inducer of apoptosis and differentiation in acute myelogenous leukemia.

Authors:  Marina Konopleva; Twee Tsao; Peter Ruvolo; Irina Stiouf; Zeev Estrov; Clinton E Leysath; Shourong Zhao; David Harris; Shirong Chang; C Ellen Jackson; Mark Munsell; Nanjoo Suh; Gordon Gribble; Tadashi Honda; W Stratford May; Michael B Sporn; Michael Andreeff
Journal:  Blood       Date:  2002-01-01       Impact factor: 22.113

4.  The novel triterpenoid CDDO induces apoptosis and differentiation of human osteosarcoma cells by a caspase-8 dependent mechanism.

Authors:  Y Ito; P Pandey; M B Sporn; R Datta; S Kharbanda; D Kufe
Journal:  Mol Pharmacol       Date:  2001-05       Impact factor: 4.436

5.  Novel triterpenoids suppress inducible nitric oxide synthase (iNOS) and inducible cyclooxygenase (COX-2) in mouse macrophages.

Authors:  N Suh; T Honda; H J Finlay; A Barchowsky; C Williams; N E Benoit; Q W Xie; C Nathan; G W Gribble; M B Sporn
Journal:  Cancer Res       Date:  1998-02-15       Impact factor: 12.701

Review 6.  NF-kappaB in cancer: from innocent bystander to major culprit.

Authors:  Michael Karin; Yixue Cao; Florian R Greten; Zhi-Wei Li
Journal:  Nat Rev Cancer       Date:  2002-04       Impact factor: 60.716

7.  Dietary flavonoid and cancer prevention: evidence and potential mechanism.

Authors:  S M Kuo
Journal:  Crit Rev Oncog       Date:  1997

8.  The synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces caspase-dependent and -independent apoptosis in acute myelogenous leukemia.

Authors:  Marina Konopleva; Twee Tsao; Zeev Estrov; Ruey-min Lee; Rui-Yu Wang; C Ellen Jackson; Teresa McQueen; Giuseppe Monaco; Mark Munsell; John Belmont; Hagop Kantarjian; Michael B Sporn; Michael Andreeff
Journal:  Cancer Res       Date:  2004-11-01       Impact factor: 12.701

9.  Design and synthesis of 2-cyano-3,12-dioxoolean-1,9-dien-28-oic acid, a novel and highly active inhibitor of nitric oxide production in mouse macrophages.

Authors:  T Honda; B V Rounds; G W Gribble; N Suh; Y Wang; M B Sporn
Journal:  Bioorg Med Chem Lett       Date:  1998-10-06       Impact factor: 2.823

10.  Synthetic triterpenoids inhibit growth and induce apoptosis in human glioblastoma and neuroblastoma cells through inhibition of prosurvival Akt, NF-kappaB and Notch1 signaling.

Authors:  Xiaohua Gao; Dorrah Deeb; Hao Jiang; Yongbo Liu; Scott A Dulchavsky; Subhash C Gautam
Journal:  J Neurooncol       Date:  2007-03-15       Impact factor: 4.130

View more
  36 in total

1.  Radiation protection of the gastrointestinal tract and growth inhibition of prostate cancer xenografts by a single compound.

Authors:  Vitali Alexeev; Elizabeth Lash; April Aguillard; Laura Corsini; Avi Bitterman; Keith Ward; Adam P Dicker; Alban Linnenbach; Ulrich Rodeck
Journal:  Mol Cancer Ther       Date:  2014-11-14       Impact factor: 6.261

2.  Antiproliferative and Apoptosis Inducing Effects of Non-Polar Fractions from Lawsonia inermis L. in Cervical (HeLa) Cancer Cells.

Authors:  Manish Kumar; Paramjeet Kaur; Subodh Kumar; Satwinderjeet Kaur
Journal:  Physiol Mol Biol Plants       Date:  2015-03-19

3.  Methyl 2-cyano-3,12-dioxooleana-1,9-dien-28-oate decreases specificity protein transcription factors and inhibits pancreatic tumor growth: role of microRNA-27a.

Authors:  Indira Jutooru; Gayathri Chadalapaka; Maen Abdelrahim; Md Riyaz Basha; Ismael Samudio; Marina Konopleva; Michael Andreeff; Stephen Safe
Journal:  Mol Pharmacol       Date:  2010-05-20       Impact factor: 4.436

4.  Combining the FLT3 inhibitor PKC412 and the triterpenoid CDDO-Me synergistically induces apoptosis in acute myeloid leukemia with the internal tandem duplication mutation.

Authors:  Rehan Ahmad; Suiyang Liu; Ellen Weisberg; Erik Nelson; Ilene Galinsky; Colin Meyer; Donald Kufe; Surender Kharbanda; Richard Stone
Journal:  Mol Cancer Res       Date:  2010-06-22       Impact factor: 5.852

5.  Synthetic oleanane triterpenoid, CDDO-Me, induces apoptosis in ovarian cancer cells by inhibiting prosurvival AKT/NF-κB/mTOR signaling.

Authors:  Xiaohua Gao; Yongbo Liu; Dorrah Deeb; Ali S Arbab; Austin M Guo; Scott A Dulchavsky; Subhash C Gautam
Journal:  Anticancer Res       Date:  2011-11       Impact factor: 2.480

6.  The role of natural products in revealing NRF2 function.

Authors:  Donna D Zhang; Eli Chapman
Journal:  Nat Prod Rep       Date:  2020-05-13       Impact factor: 13.423

7.  Oxidative Stress Attenuates Lipid Synthesis and Increases Mitochondrial Fatty Acid Oxidation in Hepatoma Cells Infected with Hepatitis C Virus.

Authors:  Donna N Douglas; Christopher Hao Pu; Jamie T Lewis; Rakesh Bhat; Anwar Anwar-Mohamed; Michael Logan; Garry Lund; William R Addison; Richard Lehner; Norman M Kneteman
Journal:  J Biol Chem       Date:  2015-12-01       Impact factor: 5.157

Review 8.  Oleanolic acid and its synthetic derivatives for the prevention and therapy of cancer: preclinical and clinical evidence.

Authors:  Muthu K Shanmugam; Xiaoyun Dai; Alan Prem Kumar; Benny K H Tan; Gautam Sethi; Anupam Bishayee
Journal:  Cancer Lett       Date:  2014-01-30       Impact factor: 8.679

9.  Oleanolic acid inhibits cell survival and proliferation of prostate cancer cells in vitro and in vivo through the PI3K/Akt pathway.

Authors:  Xuechao Li; Yarong Song; Peng Zhang; Hongxue Zhu; Lifeng Chen; Yajun Xiao; Yifei Xing
Journal:  Tumour Biol       Date:  2015-12-18

Review 10.  Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.

Authors:  Karen T Liby; Michael B Sporn
Journal:  Pharmacol Rev       Date:  2012-09-10       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.